A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 51/08 (2006.01) A61K 31/551 (2006.01) A61K 51/04 (2006.01) C07D 401/12 (2006.01) C07D 401/14 (2006.01) C07D 403/12 (2006.01) C07D 403/14 (2006.01) C07F 9/645 (2006.01) C07F 9/6558 (2006.01) C07K 5/02 (2006.01) C07K 5/06 (2006.01) C07K 5/072 (2006.01) C07K 5/083 (2006.01) C07K 7/02 (2006.01) C07K 7/52 (2006.01) C07K 14/78 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2412849
The present invention describes novel compounds of the formula:(Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer in combination therapy in a patient. The present invention provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
La présente invention concerne de nouveaux composés de la formule Q¿d?-L¿n?-C¿n?, utiles pour le diagnostic et le traitement du cancer dans une thérapie combinée chez un patient. La présente invention permet d'obtenir de nouveaux composés utiles au traitement de la polyarthrite rhumatoïde. Les agents pharmaceutiques comprennent une fraction de ciblage se fixant à un récepteur lequel est régulé positivement pendant l'angiogénèse, un groupe de liaison facultatif ainsi qu'un radio-isotope thérapeutiquement efficace ou une fraction imageable efficace du point de vue du diagnostic.
Barrett John A.
Carpenter Alan P. Jr.
Cheesman Edward H.
Rajopadhye Milind
Sworin Michael
Bristol-Myers Squibb Pharma Company
Gowling Lafleur Henderson Llp
LandOfFree
Vitronectin receptor antagonist pharmaceuticals for use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vitronectin receptor antagonist pharmaceuticals for use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vitronectin receptor antagonist pharmaceuticals for use in... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1644459